Export of herbal biotech products regulation

Introduction

Export of herbal biotech products regulation refers to the legal framework governing the manufacture, quality control, certification, packaging and international trade of herbal products developed through biotechnology or advanced biological processing techniques.

Herbal biotech products include plant-based medicines, herbal extracts, nutraceuticals, bioactive compounds, fermented herbal preparations and plant-derived pharmaceutical ingredients. Biotechnology may be used to improve the extraction, purification, cultivation, preservation and production of these products.

India has a significant herbal and medicinal plant industry because of its traditional knowledge, biodiversity and established systems of Ayurveda, Siddha and Unani medicine. However, exporting these products requires compliance with domestic manufacturing standards, intellectual property laws, biodiversity regulations and importing-country requirements.

The regulatory framework aims to protect consumers, prevent misleading medicinal claims, ensure product quality and promote sustainable use of medicinal plants.

Meaning and importance of herbal biotech export regulation

Herbal biotech export regulation involves government supervision of products manufactured using medicinal plants and biotechnology-based processes before they enter international markets.

For example, an Indian company manufacturing a standardised herbal extract through biotechnology-assisted cultivation may need to comply with applicable quality standards, manufacturing requirements, export documentation and destination-country regulations.

The main objectives include:

Consumer protection: Ensuring that herbal products meet appropriate safety and quality standards.

Product authenticity: Preventing adulteration and misidentification of medicinal plants.

Quality assurance: Maintaining consistency in extraction, purification and manufacturing.

Biodiversity conservation: Preventing unsustainable exploitation of medicinal plants.

International trade compliance: Meeting importing-country requirements.

Traditional knowledge protection: Preventing unauthorised commercial exploitation of traditional medicinal knowledge.

Legal framework in India

1. Drugs and Cosmetics Act, 1940

The Act provides the principal regulatory framework for drugs manufactured and marketed in India, including Ayurvedic, Siddha and Unani medicines.

Section 3(a) defines Ayurvedic, Siddha or Unani drugs. Section 33EEC identifies circumstances in which an Ayurvedic, Siddha or Unani drug is considered misbranded, adulterated or spurious.

Manufacturers must comply with applicable licensing, quality and labelling requirements. The classification of a herbal biotech product determines the relevant regulatory pathway.

2. Drugs and Cosmetics Rules, 1945

The Rules prescribe requirements relating to manufacturing licences, labelling, quality standards and good manufacturing practices.

Part XVI contains provisions concerning Ayurvedic, Siddha and Unani medicines. Schedule T establishes Good Manufacturing Practices requirements for relevant manufacturing facilities.

A product classified as a modern pharmaceutical drug rather than a traditional medicine may be subject to a different regulatory pathway.

3. Biological Diversity Act, 2002

The Act regulates access to biological resources and associated traditional knowledge within its statutory scope.

It is particularly relevant where herbal biotech products use medicinal plants obtained from Indian biological resources. Applicable access and benefit-sharing requirements must be considered in light of the Act, including its 2023 amendments and implementing rules.

4. Foreign Trade (Development and Regulation) Act, 1992

The Act provides the legal foundation for regulating exports from India. Section 3 empowers the Central Government to regulate foreign trade.

The Directorate General of Foreign Trade (DGFT) implements export policies through the Foreign Trade Policy and ITC (HS) classification. Exporters must verify whether their herbal products are freely exportable, restricted or subject to specific conditions.

5. Customs Act, 1962

The Customs Act regulates the movement of goods across India's borders. Exporters must comply with customs declarations, product classification, valuation and applicable documentation requirements.

6. Geographical Indications of Goods (Registration and Protection) Act, 1999

The Act protects geographical indications associated with goods originating from particular geographical regions. It may be relevant where herbal products use protected geographical names or region-specific traditional products.

International regulatory framework

1. Convention on Biological Diversity, 1992

The Convention promotes biodiversity conservation, sustainable use of biological resources and fair sharing of benefits arising from genetic resources.

It is important for herbal biotech exports involving medicinal plants and biological resources.

2. Nagoya Protocol, 2010

The Protocol establishes an international framework for access to genetic resources and fair and equitable benefit-sharing. It may apply to relevant herbal biotechnology research and commercialisation activities involving genetic resources obtained from another country.

3. Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), 1973

CITES regulates international trade in listed endangered plant and animal species. Certain medicinal plants and herbal ingredients may require export permits or certificates depending on their listing and applicable exemptions.

4. Codex Alimentarius

Codex standards provide international guidance on food safety, food additives, contaminants and labelling. They may be relevant when herbal biotech products are exported as foods or dietary supplements.

5. World Trade Organization Agreements

The WTO Agreement on Sanitary and Phytosanitary Measures and the Agreement on Technical Barriers to Trade may become relevant when importing countries impose food safety, plant-health, technical or labelling requirements.

Important judicial decisions

There are limited Indian judicial decisions specifically concerning the export regulation of herbal biotechnology products. However, several judgments establish important principles relating to traditional knowledge, biodiversity, patents and medicinal products.

1. Novartis AG v. Union of India (2013)

The Supreme Court interpreted Section 3(d) of the Patents Act, 1970, and rejected Novartis's patent application concerning the beta-crystalline form of imatinib mesylate.

The judgment is relevant to herbal biotechnology because it demonstrates that incremental pharmaceutical developments must satisfy statutory patentability requirements. It also helps prevent inappropriate monopolisation of known medicinal substances.

2. Divya Pharmacy v. Union of India (2018)

The Uttarakhand High Court examined the applicability of benefit-sharing obligations under the Biological Diversity Act to the use of biological resources by Indian entities.

The decision is relevant to businesses commercialising medicinal plants and herbal products because it addresses the relationship between biological-resource utilisation and benefit-sharing obligations.

3. State of West Bengal v. Kesoram Industries Ltd. (2004)

The Supreme Court examined legislative competence and the interpretation of statutory taxation powers. Although not directly concerned with herbal products, the decision is relevant to understanding the constitutional allocation of regulatory and fiscal powers affecting commercial activities.

4. R.G. Anand v. Deluxe Films (1978)

The Supreme Court explained principles concerning copyright protection and the distinction between ideas and their expression. This judgment is relevant by analogy to the protection of herbal formulations, research documentation and commercially developed product materials. Traditional knowledge itself cannot automatically be monopolised through copyright.

5. Intellectual Property Rights in Traditional Knowledge: Turmeric Patent Revocation (1997)

The United States Patent and Trademark Office revoked a patent granted for turmeric's wound-healing use after traditional knowledge was established as prior art.

This was a foreign patent-office proceeding, not an Indian court judgment. It nevertheless demonstrates the importance of protecting traditional medicinal knowledge against inappropriate patent claims.

Major regulatory challenges

Herbal biotech exporters face several challenges because importing countries classify herbal products differently. A preparation treated as an Ayurvedic medicine in India may be classified as a food supplement, traditional medicine or pharmaceutical product elsewhere.

Other important challenges include:

Differences in international quality and safety standards.

Testing for contaminants, pesticides and heavy metals.

Verification of botanical identity and ingredient purity.

Protection of traditional knowledge and intellectual property.

Compliance with biodiversity access and benefit-sharing rules.

Restrictions on endangered medicinal plant species.

Accurate labelling and substantiation of health claims.

Compliance requirements and safeguards

Manufacturers and exporters should establish a complete compliance system before entering international markets.

Important measures include:

Determine whether the product is classified as an Ayurvedic medicine, modern drug, food or nutraceutical.

Obtain the applicable manufacturing and product approvals.

Maintain quality-control and laboratory-testing records.

Verify the lawful sourcing of medicinal plants.

Obtain required biodiversity permissions and benefit-sharing compliance.

Check CITES restrictions where listed plant species are involved.

Verify destination-country import, labelling and certification requirements.

Maintain accurate export invoices, product descriptions and customs documentation.

Conclusion

Export regulation of herbal biotech products involves a combination of pharmaceutical law, food safety, biodiversity conservation, intellectual property protection and international trade regulation. In India, the Drugs and Cosmetics Act, Biological Diversity Act, Foreign Trade Act and Customs Act provide important regulatory foundations. International frameworks such as the Convention on Biological Diversity, Nagoya Protocol and CITES establish additional obligations. Judicial decisions including Novartis AG v. Union of India and Divya Pharmacy v. Union of India provide relevant principles concerning patentability and benefit-sharing. Effective regulation requires product-specific classification, scientific quality assessment, lawful sourcing and compliance with importing-country standards.